Patents Examined by S. Gollamudi
-
Patent number: 7264824Abstract: Oral dosage form for food and food supplement as well as dietetics comprising polyunsaturated acids in a xylose-hardened gelatine capsule with a retarded release time.Type: GrantFiled: April 13, 2000Date of Patent: September 4, 2007Assignee: Meduna Arzneimittel GmbHInventor: Friedel Frauendorfer
-
Patent number: 7247317Abstract: Novel compositions for the treatment of IRDS and ARDS are indicated which contain a compound of formula (I), in which R1 is hydrogen or 2-(2-hydroxyethoxy)ethyl and/or a pharmacologically tolerable salt of this compound and lung surfactantType: GrantFiled: April 16, 2004Date of Patent: July 24, 2007Assignee: Altana Pharma AGInventor: Dietrich Häfner
-
Patent number: 7141249Abstract: A fast-dissolving pharmaceutical composition comprising micronized (R)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3?-pyrrolidine-1,2?,3,5?-tetrone (hereinafter, referred to as AS-3201). The present pharmaceutical composition has improved dissolution characteristics as well as a good bioavailability.Type: GrantFiled: October 15, 1998Date of Patent: November 28, 2006Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Mamoru Ohashi, Kazuyoshi Ogasawara, Yoshimi Shirai, Hiroshi Fujioka
-
Patent number: 7128933Abstract: An orally ingestible composition for the treatment of external personal odors can include about 35% w/w to about 50% w/w of the essential oil of lavender, about 1% w/w to about 10% w/w of the essential oil of rosemary, about 1% w/w to about 10% w/w of the essential oil of sage, and sufficient carrier medium to make up to 100% by weight.Type: GrantFiled: May 16, 2003Date of Patent: October 31, 2006Inventors: Mitchell Kurk, Odilza Vital
-
Patent number: 7105172Abstract: Disclosed herein are methods for the treatment or prevention of rosacea in a patient, including administering a compound that inhibits one or more components of the bradykinin activation pathway in an amount sufficient to reduce or prevent one or more symptoms of rosacea.Type: GrantFiled: November 17, 2000Date of Patent: September 12, 2006Inventor: John D. Bolla
-
Patent number: 7087238Abstract: A sheet-like pack effective for prevention and improvement of small wrinkles on skin, comprising a water soluble high molecular weight compound, water and ubiquinone 10 as an active ingredient, which are contained in a base.Type: GrantFiled: November 7, 2001Date of Patent: August 8, 2006Assignees: Teikoku Seiyaku Co., LTD, Beirsdorf AktiengesellschaftInventors: Hidetoshi Hamamoto, Yasuko Abe, Sven H. Gohla, Heiner Max, Thorsten Cassier
-
Patent number: 7083820Abstract: The present invention relates to a process for dehydrating naturally occurring organic materials which contain a biologically active component, and in particular proteins, which does not change the original structure of the active component, by drying such material in particulate form in the presence of an antimicrobial agent and preferably an ionizable salt at temperatures at or below which denaturization occurs until the water content of the material is reduced to less than 15%.Type: GrantFiled: September 25, 2001Date of Patent: August 1, 2006Inventors: Marvin L. Schilling, Richard D. Fafard
-
Patent number: 7037489Abstract: Skin external agent compositions and drugs characterized by containing fumaric acid diester derivatives represented by following general formula (1), wherein R1 represents C1-4 alkylene; R2 and R3 represent each liner or branched C1-8 alkyl; and n is an integer of 2 to 5; which provide epidermal barrier function potentiating agents and skin external agent compositions having a high safety, quickly relieving epidermal permeation barrier function failures and having an effect of maintaining the skin in a cosmetologically healthy state; agents to be used together with HB-EFG expression inducing agents accelerating epidermal turnover, amphiregulin expression inhibitors regulating excessive epidermal proliferation, and retinoic acid or its derivative preventing skin chapping caused by retinoic acid or its derivative; and skin aging relieving agents capable of ameliorating depression in the skin metabolism and thinning in association with aging.Type: GrantFiled: December 15, 2000Date of Patent: May 2, 2006Assignee: Kanebo Cosmetics, Inc.Inventors: Hideyo Uchiwa, Sachiyo Hirotsu, Akinori Haratake, Takeshi Ikemoto, Junichi Matsui, Shunsuke Yamazaki, Masaki Yoshida, Motoi Hayase
-
Patent number: 7029701Abstract: The invention relates to pharmaceutical compositions comprising omeprazole and aspirin wherein the combination is useful for the treatment and prevention of cardiovascular events including heart attacks and platelet aggregation leading to a potential cardiac event. A variety of drug delivery systems may be utilized to deliver the combination of active ingredients. The preferred delivery system utilizes a tablet or capsule containing an inert sugar core particle that is coated with subparticles of a coated omeprazole wherein the coating contains omeprazole, a binder, a surface active agent and a basifying agent along with a filler. The aspirin may be combined with this formulation to coat the sugar sphere or it may be part of a separate coating composition that forms a multilayer system that is ultimately coated with an enteric coating and then formed into the tablet or capsule by conventional means.Type: GrantFiled: September 10, 2001Date of Patent: April 18, 2006Assignee: Andrx Pharmaceuticals, LLCInventor: Chih-Ming Chen
-
Patent number: 7029663Abstract: A substantially anhydrous stable ointment containing Aspirin which is characterized in using gelation hydrocarbon and/or vaseline as a base. The ointment is superior in stability and can be stored for a long term.Type: GrantFiled: June 23, 1998Date of Patent: April 18, 2006Assignee: Teikoku Seiyaku Co., Ltd.Inventors: Noriko Mizobuchi, Yuichi Hasegawa, Mitsuhiro Kawada, Shin-ichi Hisaichi
-
Patent number: 7025989Abstract: An antibiotic product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours.Type: GrantFiled: August 2, 2002Date of Patent: April 11, 2006Assignee: Advancis Pharmaceutical Corp.Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
-
Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
Patent number: 7018645Abstract: A water soluble, biodegradable reverse thermal gelation system comprising a mixture of at least two types of tri-block copolymer components is disclosed. The tri-block copolymer components are made of a hydrophobic biodegradable polyester A-polymer block and a hydrophilic polyethylene glycol B-polymer block. The drug release and gel matrix erosion rates of the biodegradable reverse thermal gelation system may be modulated by various parameters such as the hydrophobic/hydrophilic component contents, polymer block concentrations, molecular weights and gelation temperatures, and weight ratios of the tri-block copolymer components in the mixture.Type: GrantFiled: April 27, 2000Date of Patent: March 28, 2006Assignee: Macromed, Inc.Inventors: Ai-Zhi Piao, Chung Shih -
Patent number: 7018648Abstract: The invention relates to a self-adhesive transdermal device for the administration of testosterone and/or at least one of the derivatives thereof, comprising successively at least one support layer, a self-adhesive matrix layer and a detachable protective layer, whereby the matrix layer comprises at least one self-adhesive polymer, at least one formulating adjuvant for the matrix layer, at least one solvent chosen from the group made up of solvents of testosterone or the derivatives thereof and testosterone and/or at least one of the derivatives thereof in an oversaturated solution. The device has excellent testosterone permeation qualities and excellent cutaneous tolerance and adhesion qualities. The invention also relates to a method for the production of said device and the use thereof for a medicament, i.e. within the framework of a testosterone replacement therapy.Type: GrantFiled: May 18, 2000Date of Patent: March 28, 2006Assignee: Pierre Fabre MedicamentInventors: Michel Sournac, Laurent Liorzou, Joël Bougaret
-
Patent number: 7008645Abstract: A method of inhibiting the activity or production of cytokines or growth factors associated with vascular restenosis, by administering to an individual an effective amount of an active ingredient comprising a bisphosphonate particle or a bisphosphonate particulate. The bisphosphonate may be encapsulated, embedded or adsorbed within the particle, dispersed uniformly in the polymer matrix, adsorbed on the particle surface, or in combination of any of these forms. The particles include liposomes or inert polymeric particles, such as microcapsules, nanocapsules, nanoparticles, nanospheres, or microparticles. The particulates include any suspended or dispersed form of the bisphosphonate which is not encapsulated, entrapped, or adsorbed within a polymeric particle. The particulates include suspended or dispersed colloids, aggregates, flocculates, insoluble salts and insoluble complexes of the active ingredient.Type: GrantFiled: May 30, 2002Date of Patent: March 7, 2006Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Gershon Golomb, Haim Danenberg
-
Patent number: 7005135Abstract: The present invention relates to resorbable glass scaffolds for use in biological applications and methods for making same. Specifically, these scaffolds are composed of phosphate glass fibers, where the rate of dissolution into biological fluids is controlled by the length of time the glass is held above its melt temperature prior to spinning the fiber.Type: GrantFiled: February 28, 2003Date of Patent: February 28, 2006Assignee: Ethicon Inc.Inventors: Victor F. Janas, Kevor S. Tenhuisen
-
Patent number: 6994872Abstract: This invention relates to a monolayer sugar-coated tablet which is coated with a sugar-coating liquid containing 30–54% by weight of saccharide, 2–10% by weight of polyethylene glycol and 0.2–2% by weight of polyvinylpyrrolidone, and a process for preparing the same. According to the invention, a monolayer sugar-coated tablet and a process for preparation thereof are provided with very great economical advantages that the skill required for conventional sugar-coating processing is unnecessary and furthermore consumption of sugar-coating material can be reduced and the processing time can be shortened.Type: GrantFiled: March 1, 2001Date of Patent: February 7, 2006Assignee: Teikoku Hormone Mfg. Co., Ltd.Inventor: Toshio Takeuchi
-
Patent number: 6984400Abstract: A method of treating or preventing restenosis by administering to an individual an effective amount of an active ingredient comprising a bisphosphonate particle or a bisphosphonate particulate. The bisphosphonate may be encapsulated, embedded or adsorbed within the particle, dispersed uniformly in the polymer matrix, adsorbed on the particle surface, or in combination of any of these forms. The particles include liposomes or inert polymeric particles, such as microcapsules, nanocapsules, nanoparticles, nanospheres, or microparticles. The particulates include any suspended or dispersed form of the bisphosphonate which is not encapsulated, entrapped, or adsorbed within a polymeric particle. The particulates include suspended or dispersed colloids, aggregates, flocculates, insoluble salts and insoluble complexes of the active ingredient.Type: GrantFiled: April 19, 2002Date of Patent: January 10, 2006Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Gershon Golomb, Haim Danenberg
-
Patent number: 6962712Abstract: Cosmetic or dermatological composition characterized in that it comprises a combination of an elastase inhibitor of the N-acylaminoamide family and at least one antifungal agent or at least one antibacterial agent.Type: GrantFiled: June 26, 2002Date of Patent: November 8, 2005Assignee: L'OrealInventors: Lionel Breton, Yann Mahe
-
Patent number: 6960351Abstract: An immunoisolatory vehicle for the implantation into an individual of cells which produce a needed product or provide a needed metabolic function. The vehicle is comprised of a core region containing isolated cells and materials sufficient to maintain the cells, and a permselective, biocompatible, peripheral region free of the isolated cells, which immunoisolates the core yet provides for the delivery of the secreted product or metabolic function to the individual. The vehicle is particularly well-suited to delivery of insulin from immunoisolated islets of Langerhans, and can also be used advantageously for delivery of high molecular weight products, such as products larger than IgG. A method of making a biocompatible, immunoisolatory implantable vehicle, consisting in a first embodiment of a coextrusion process, and in a second embodiment of a stepwise process.Type: GrantFiled: July 21, 2003Date of Patent: November 1, 2005Assignee: Brown University Research FoundationInventors: Keith E. Dionne, Dwaine F. Emerich, Diane Hoffman, Paul R. Sanberg, Lisa Christenson, Orion D. Hegre, David W. Scharp, Paul E. Lacy, Patrick Aebischer, Alfred V. Vasconcellos, Michael J. Lysaght, Frank T. Gentile
-
Patent number: 6953590Abstract: A preparation for transdermal absorption is disclosed which is suited for alleviating lasting pains caused by herpes zoster or postherpetic neuralgia and is practical and more improved in drug efficacy, safety and application characteristics. This tape preparation for transdermal absorption is obtained by causing an adhesive mass prepared by incorporating 1–30 parts by weight of a local anesthetic as an active ingredient in 100 parts by weight of a nonaqueous adhesive mass base comprising 5–50% by weight of a styrene-isoprene-styrene block copolymer, 1–60% by weight of an alicyclic saturated hydrocarbon resin, 5–60% by weight of liquid paraffin and 1–30% by weight of butyl rubber to be supported on a backing.Type: GrantFiled: September 9, 1999Date of Patent: October 11, 2005Assignees: Yutoku Pharmaceutical Ind. Co., Ltd., Maruho Kabushiki KaishaInventors: Yukino Owaki, Michiyo Hashimoto, Isamu Sakamoto, Kunio Takiguchi, Yoetsu Toyoshima